BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li T, Ke W, Sun P, Chen X, Belgaumkar A, Huang Y, Xian W, Li J, Zheng Q. Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis. BMJ Open. 2016;6:e010902. [PMID: 27147389 DOI: 10.1136/bmjopen-2015-010902] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Sinha R, Lockman KA, Mallawaarachchi N, Robertson M, Plevris JN, Hayes PC. Carvedilol use is associated with improved survival in patients with liver cirrhosis and ascites. J Hepatol. 2017;67:40-46. [PMID: 28213164 DOI: 10.1016/j.jhep.2017.02.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 8.8] [Reference Citation Analysis]
2 Ahmed HMS, Mohamed SG, Ibrahim WS, Rezk AM, Mahmoud AAA, Mahmoud MF, Ibrahim IAAE. Acute and chronic metabolic effects of carvedilol in high-fructose, high-fat diet-fed mice: implication of β-arrestin2 pathway. Can J Physiol Pharmacol 2021;:1-10. [PMID: 34570983 DOI: 10.1139/cjpp-2021-0299] [Reference Citation Analysis]
3 Wu Y, Li Z, Xiu AY, Meng DX, Wang SN, Zhang CQ. Carvedilol attenuates carbon tetrachloride-induced liver fibrosis and hepatic sinusoidal capillarization in mice. Drug Des Devel Ther 2019;13:2667-76. [PMID: 31534314 DOI: 10.2147/DDDT.S210797] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
4 Afaa TJ, Amegan-Aho KH, Richardson E, Goka B. Diagnosis and management of extrahepatic oesophageal variceal bleed in children in a low resourced setting. Ghana Med J 2020;54:274-8. [PMID: 33883777 DOI: 10.4314/gmj.v54i4.11] [Reference Citation Analysis]
5 Karagiannakis DS, Voulgaris T, Siakavellas SI, Papatheodoridis GV, Vlachogiannakos J. Evaluation of portal hypertension in the cirrhotic patient: hepatic vein pressure gradient and beyond. Scand J Gastroenterol 2018;53:1153-64. [PMID: 30345856 DOI: 10.1080/00365521.2018.1506046] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
6 Aggeletopoulou I, Konstantakis C, Manolakopoulos S, Triantos C. Role of band ligation for secondary prophylaxis of variceal bleeding. World J Gastroenterol 2018;24:2902-14. [PMID: 30018485 DOI: 10.3748/wjg.v24.i26.2902] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Kalambokis GN, Christaki M, Tsiakas I, Despotis G, Fillipas-Ntekouan S, Fotopoulos A, Tsiouris S, Xourgia X, Lakkas L, Pappas K, Michalis LK, Sergianiti F, Baltayiannis G, Christodoulou D, Koustousi C, Aggelis N, Milionis H. Conversion of Propranolol to Carvedilol Improves Renal Perfusion and Outcome in Patients With Cirrhosis and Ascites. J Clin Gastroenterol 2021;55:721-9. [PMID: 32991355 DOI: 10.1097/MCG.0000000000001431] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 European Association for the Study of the Liver. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69:406-460. [PMID: 29653741 DOI: 10.1016/j.jhep.2018.03.024] [Cited by in Crossref: 660] [Cited by in F6Publishing: 520] [Article Influence: 165.0] [Reference Citation Analysis]
9 Roston TM, Chua D, Lum E, Krahn AD. Switching Between β-Blockers: An Empiric Tool for the Cardiovascular Practitioner. Can J Cardiol 2019;35:539-43. [PMID: 30935645 DOI: 10.1016/j.cjca.2019.01.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Wei ZG, Wei FX, Shao ZW, Su GH, Qi XP, Zhang YC. Lowering hepatic venous pressure agent carvedilol versus variceal banding ligation for clinical outcomes of cirrhotic portal hypertension. Ther Clin Risk Manag 2019;15:45-57. [PMID: 30636878 DOI: 10.2147/TCRM.S184863] [Reference Citation Analysis]
11 Perez I, Bolte FJ, Bigelow W, Dickson Z, Shah NL. Step by Step: Managing the Complications of Cirrhosis. Hepat Med 2021;13:45-57. [PMID: 34079394 DOI: 10.2147/HMER.S278032] [Reference Citation Analysis]
12 Vilaseca M, Guixé-Muntet S, Fernández-Iglesias A, Gracia-Sancho J. Advances in therapeutic options for portal hypertension. Therap Adv Gastroenterol 2018;11:1756284818811294. [PMID: 30505350 DOI: 10.1177/1756284818811294] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
13 Yoon U, Topper J, Goldhammer J. Preoperative Evaluation and Anesthetic Management of Patients With Liver Cirrhosis Undergoing Cardiac Surgery. J Cardiothorac Vasc Anesth 2020:S1053-0770(20)30816-8. [PMID: 32891522 DOI: 10.1053/j.jvca.2020.08.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Sauerbruch T, Schierwagen R, Trebicka J. Managing portal hypertension in patients with liver cirrhosis. F1000Res 2018;7:F1000 Faculty Rev-533. [PMID: 29780579 DOI: 10.12688/f1000research.13943.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 6] [Article Influence: 3.8] [Reference Citation Analysis]
15 Bunchorntavakul C, Reddy KR. Pharmacologic Management of Portal Hypertension. Clin Liver Dis 2019;23:713-36. [PMID: 31563219 DOI: 10.1016/j.cld.2019.06.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Tripathi D, Stanley AJ. Editorial: optimal dose of carvedilol in portal hypertension…nearly there. Aliment Pharmacol Ther 2018;47:1328-9. [PMID: 29644737 DOI: 10.1111/apt.14607] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
17 Malandris K, Paschos P, Katsoula A, Manolopoulos A, Andreadis P, Sarigianni M, Athanasiadou E, Akriviadis E, Tsapas A. Carvedilol for prevention of variceal bleeding: a systematic review and meta-analysis. Ann Gastroenterol 2019;32:287-97. [PMID: 31040627 DOI: 10.20524/aog.2019.0368] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
18 Dwinata M, Putera DD, Adda’i MF, Hidayat PN, Hasan I. Carvedilol vs endoscopic variceal ligation for primary and secondary prevention of variceal bleeding: Systematic review and meta-analysis. World J Hepatol 2019; 11(5): 464-476 [PMID: 31183006 DOI: 10.4254/wjh.v11.i5.464] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 3.7] [Reference Citation Analysis]
19 Atwa A, Hegazy R, Shaffie N, Yassin N, Kenawy S. Protective Effects of Vasodilatory Βeta-Blockers Carvedilol and Nebivolol against Glycerol Model of Rhabdomyolysis-Induced Acute Renal Failure in Rats. Open Access Maced J Med Sci 2016;4:329-36. [PMID: 27703551 DOI: 10.3889/oamjms.2016.082] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
20 Alqahtani SA, Jang S. Pathophysiology and Management of Variceal Bleeding. Drugs 2021;81:647-67. [PMID: 33710585 DOI: 10.1007/s40265-021-01493-2] [Reference Citation Analysis]
21 Zacharias AP, Jeyaraj R, Hobolth L, Bendtsen F, Gluud LL, Morgan MY. Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices. Cochrane Database Syst Rev. 2018;10:CD011510. [PMID: 30372514 DOI: 10.1002/14651858.cd011510.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
22 Sharma S, Agarwal S, Gunjan D, Kaushal K, Anand A, Mohta S, Shalimar, Saraya A. Long-term Outcomes with Carvedilol versus Propranolol in Patients with Index Variceal Bleed: 6-year Follow-up Study. J Clin Exp Hepatol 2021;11:343-53. [PMID: 33994717 DOI: 10.1016/j.jceh.2020.08.009] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
23 Guixé-muntet S, Zhu C, Xie W, Gracia-sancho J. Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. Pharmacology & Therapeutics 2020;215:107626. [DOI: 10.1016/j.pharmthera.2020.107626] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
24 El-demerdash E, Abdel-sattar SA, El-bakly WM, Mohamed EA. Antifibrotic Effects of Carvedilol and Impact of Liver Fibrosis on Carvedilol Pharmacokinetics in a Rat model. Eur J Drug Metab Pharmacokinet 2017;42:767-79. [DOI: 10.1007/s13318-016-0391-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
25 de Mattos ÂZ, Terra C, Farias AQ, Bittencourt PL, Alliance of Brazilian Centers for Cirrhosis Care–the ABC Group. Primary prophylaxis of variceal bleeding in patients with cirrhosis: A comparison of different strategies. World J Gastrointest Endosc 2021; 13(12): 628-637 [DOI: 10.4253/wjge.v13.i12.628] [Reference Citation Analysis]